A Phase 3 interventional study of Imatinib and Placebo in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Terminated at 59 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 3rd largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 3, and was the 3rd registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 15 more countries
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 6
First in 2006; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 144 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 27 across the 12 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multinational, multi center extension study. This study will provide data on the long-term safety, tolerability, and efficacy of imatinib in the treatment of severe pulmonary arterial hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
Drug: Imatinib · Drug: Placebo
Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
Drug: Imatinib · Drug: Placebo
Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
Number of Participants With Adverse Events, Serious Adverse Events and Deaths
Adverse event monitoring was conducted throughout the study.
Time frame: 204 weeks
Change From Core Study Baseline in Six-Minute Walk Distance (6MWD)
A six minute walk test (6MWT) was performed in accordance with the guidleines of the American Thoracic Society (2002).
Time frame: core study baseline, extension baseline, 12 weeks, 24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 156 weeks, 204 weeks
Percentage of Participants With Incidence of Clinical Worsening Events
Clinical worsening events included death, overnight hospitalization for worsening of PAH, worsening of World Health Organization (WHO) functional class by at least one level (drop in WHO ), 15% decrease in the 6MWD as compared to baseline confirmed by two 6MWTs at two consecutive study visits (6MWD reduction), and drop in WHO \& 6MWD reduction. Some participants have fulfilled more than one criterion. Therefore, the sum of individual components may be higher than the total number of participants with clinical worsening.
Time frame: 204 weeks
| Milestone | Core Imatinib | Core Placebo |
|---|---|---|
| Started | 66 | 78 |
| Completed | 5 | 4 |
| Not completed | 61 | 74 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Subject no longer requires study drug | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Abnormal test procedure result | 2 | 0 |
| Withdrew: Lack of efficacy | 3 | 4 |
| Withdrew: Death | 5 | 10 |
| Withdrew: Withdrawal by subject | 5 | 10 |
| Withdrew: Adverse event | 19 | 26 |
| Withdrew: Administrative problems | 25 | 22 |
Adverse event monitoring was conducted throughout the study.
| Participants | Core Imatinib | Core Placebo |
|---|---|---|
| Adverse events (non-serious and serious) | 62 | 76 |
| Serious adverse events | 40 | 53 |
| Deaths | 6 | 10 |
A six minute walk test (6MWT) was performed in accordance with the guidleines of the American Thoracic Society (2002).
| meters | Core Imatinib | Core Placebo |
|---|---|---|
| Extension baseline (n=61,77) | 42.98 ± 55.209 | 4.91 ± 62.629 |
| Week 12 (n=58,57) | 48.75 ± 60.887 | 16.25 ± 64.992 |
| Week 24 (n=54,53) | 44.71 ± 45.506 | 19.34 ± 71.675 |
| Week 48 (n=47,42) | 45.81 ± 72.150 | 29.18 ± 65.198 |
| Week 72 (n=40,39) | 49.54 ± 76.019 | 56.46 ± 111.130 |
| Week 96 (n=38,35) | 66.64 ± 71.080 | 41.03 ± 54.495 |
| Week 120 (n=32,29) | 83.19 ± 67.855 | 37.43 ± 60.087 |
| Week 144 (n=27,21) | 67.70 ± 64.000 | 39.45 ± 79.356 |
| Week 156 (n=21,18) | 72.60 ± 67.972 | 30.17 ± 66.856 |
| Week 204 (n=4,3) | 96.88 ± 42.048 | 4.50 ± 25.608 |
Clinical worsening events included death, overnight hospitalization for worsening of PAH, worsening of World Health Organization (WHO) functional class by at least one level (drop in WHO ), 15% decrease in the 6MWD as compared to baseline confirmed by two 6MWTs at two consecutive study visits (6MWD reduction), and drop in WHO \& 6MWD reduction. Some participants have fulfilled more than one criterion. Therefore, the sum of individual components may be higher than the total number of participants with clinical worsening.
| Percentage of participants | Core Imatinib | Core Placebo |
|---|---|---|
| Total participants with clinical worsening | 50.0 | 46.2 |
| Death (all deaths) | 7.6 | 12.8 |
| Hospitalization for worsening of PAH | 33.3 | 28.2 |
| Drop in WHO | 24.2 | 19.2 |
| 6MWD reduction | 12.1 | 19.2 |
| Drop in WHO and 6MWD reduction | 1.5 | 3.8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Core Imatinib | — | 40/66 (60.6%) | 55/66 (83.3%) |
| Core Placebo | — | 53/78 (67.9%) | 72/78 (92.3%) |
| Event | Core Imatinib | Core Placebo |
|---|---|---|
| Right ventricular failureCardiac disorders | 5/66 | 8/78 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 6/66 | 8/78 |
| SyncopeNervous system disorders | 2/66 | 7/78 |
| Device related infectionInfections and infestations | 5/66 | 3/78 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/66 | 5/78 |
| AnaemiaBlood and lymphatic system disorders | 3/66 | 2/78 |
| PneumoniaInfections and infestations | 3/66 | 3/78 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 3/66 | 1/78 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/66 | 2/78 |
| LeukopeniaBlood and lymphatic system disorders | 0/66 | 3/78 |
| Event | Core Imatinib | Core Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 21/66 | 39/78 |
| Oedema peripheralGeneral disorders | 21/66 | 32/78 |
| DiarrhoeaGastrointestinal disorders | 18/66 | 27/78 |
| VomitingGastrointestinal disorders | 14/66 | 25/78 |
| NasopharyngitisInfections and infestations | 17/66 | 24/78 |
| HeadacheNervous system disorders | 12/66 | 24/78 |
| Periorbital oedemaEye disorders | 11/66 | 23/78 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/66 | 11/78 |
| RashSkin and subcutaneous tissue disorders | 7/66 | 13/78 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/66 | 12/78 |
| Age, Continuous(Years) | Core Imatinib | Core Placebo | Total |
|---|---|---|---|
| Mean | 49.3 ± 15.52 | 45.7 ± 13.31 | 47.4 ± 14.42 |
| Sex: Female, Male(Participants) | Core Imatinib | Core Placebo | Total |
|---|---|---|---|
| Female | 57 | 63 | 120 |
| Male | 9 | 15 | 24 |
The record gives a start of Apr 2010, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib
Pulmonary Arterial Hypertension →